Dr. Kieron Dunleavy's Guide On What To Expect From CLL Treatment

Dr. Dunleavy stresses that clinical markers often outweigh molecular markers, especially when a patient feels well and shows stable lab trends.

The first several weeks of CLL treatment — whether starting a BTK inhibitor or a fixed‑duration venetoclax/obinutuzumab regimen — are typically the most demanding, with side effects, frequent labs, and closer monitoring.

BTK inhibitors (Bruton’s tyrosine kinase inhibitors) are generally well-tolerated treatments for chronic lymphocytic leukemia (CLL), with most patients experiencing only mild, manageable side effects such as minor GI issues, skin changes, easy bruising, or a petechial rash.